Berenberg has downgraded Eli Lilly and Co (LLY) from a Buy to a Hold rating as of September 16, 2025. The current share price stands at $1,055.18.
This move underscores a shift in sentiment regarding the company's outlook, potentially reflecting increased caution amid competitive pressures, market conditions, or execution risks that could affect performance.
Eli Lilly, headquartered in Indianapolis, Indiana, is a major player in the pharmaceuticals industry. The company employs approximately 47,000 full-time staff and specializes in the discovery, development, manufacture, and sale of pharmaceutical products. Its robust portfolio includes cardiometabolic health products like Humalog and Trulicity, oncology medications such as Verzenio, and immunology treatments like Taltz. Eli Lilly's market capitalization is currently $992.3 billion, with a P/E ratio of 53.89 and a dividend yield of 57.2%.
Analyst ratings, including this recent downgrade, serve as professional opinions based on extensive research and financial modeling. While they can provide valuable insights, they also reflect assumptions that may not materialize. Investors are encouraged to consider a range of factors, including company fundamentals and industry trends, when making decisions.
Eli Lilly's analyst consensus remains positive, with 9 Strong Buy, 18 Buy, and 9 Hold ratings from a total of 36 analysts as of November 1, 2025.
The landscape for Eli Lilly could continue to evolve as new information becomes available, leading to potential adjustments in analyst perspectives.